$1.59
9.66% yesterday
NYSE, May 20, 10:01 pm CET
ISIN
US92332V1070
Symbol
VTYX
Sector
Industry

Ventyx Biosciences Stock price

$1.59
+0.46 40.71% 1M
-0.13 7.56% 6M
-0.60 27.40% YTD
-3.24 67.08% 1Y
-16.85 91.38% 3Y
-19.43 92.44% 5Y
-19.43 92.44% 10Y
NYSE, Closing price Tue, May 20 2025
+0.14 9.66%
ISIN
US92332V1070
Symbol
VTYX
Sector
Industry

Key metrics

Market capitalization $113.15m
Enterprise Value $-105.11m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.96
P/B ratio (TTM) P/B ratio 0.49
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-136.48m
Free Cash Flow (TTM) Free Cash Flow $-109.05m
Cash position $228.81m
EPS (TTM) EPS $-1.75
P/E forward negative
Short interest 10.78%
Show more

Is Ventyx Biosciences a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Ventyx Biosciences Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Ventyx Biosciences forecast:

6x Buy
67%
3x Hold
33%

Analyst Opinions

9 Analysts have issued a Ventyx Biosciences forecast:

Buy
67%
Hold
33%

Financial data from Ventyx Biosciences

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs 1.30 1.30
7% 7%
-
-1.30 -1.30
7% 7%
-
- Selling and Administrative Expenses 28 28
8% 8%
-
- Research and Development Expense 106 106
39% 39%
-
-135 -135
34% 34%
-
- Depreciation and Amortization 1.30 1.30
7% 7%
-
EBIT (Operating Income) EBIT -136 -136
33% 33%
-
Net Profit -124 -124
36% 36%
-

In millions USD.

Don't miss a Thing! We will send you all news about Ventyx Biosciences directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Ventyx Biosciences Stock News

Neutral
GlobeNewsWire
12 days ago
Topline data from multiple Phase 2 studies expected throughout 2025 • Q2 readout from VTX3232 study in patients with early Parkinson's disease • H2 readout from VTX2735 study in patients with recurrent pericarditis • H2 readout from VTX3232 study in participants with obesity and cardiometabolic risk factors Cash, cash equivalents and marketable securities balance of $228.8M as of March 31, 2025...
Neutral
GlobeNewsWire
about 2 months ago
Appointment of seven recognized experts is validating for Ventyx's NLRP3 Program -- AD/PD™ 2025 provides helpful insights on potential next steps in Parkinson's disease SAN DIEGO, April 01, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for autoimmune, inflammatory...
Neutral
GlobeNewsWire
3 months ago
Topline data readouts from multiple Phase 2 studies expected throughout 2025 VTX2735 in patients with recurrent pericarditis in H2 VTX3232 in participants with obesity and cardiometabolic risk factors in H2 VTX3232 biomarker study in patients with early Parkinson's disease in Q2 Cash, cash equivalents and marketable securities balance of $252.9M as of December 31, 2024 expected to fund operatio...
More Ventyx Biosciences News

Company Profile

Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing novel small molecule therapeutics for the treatment of autoimmune diseases. Its clinical stage pipeline includes VTX958, a Phase 1 allosteric TYK2 inhibitor for the treatment of a broad range of autoimmune diseases, VTX002, a Phase 2-ready S1P1 receptor modulator for the treatment of ulcerative colitis, and VTX2735, a Phase 1-ready peripheral inhibitor of the NLRP3 inflammasome, which is a mediator of multiple inflammatory conditions. The company was founded on November 21, 2018 and is headquartered in San Diego, CA.

Head office United States
CEO Raju Mohan
Employees 82
Founded 2018
Website www.ventyxbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today